Age‐related sarcopenia or cachexia is associated with a decrease in muscle mass and strength; this reduces the quality of life and increases nursing care requirements and mortality.1, 2, 3 Sarcopenia and cachexia represent unmet needs, and the sarcopenia medical care guidelines were established recently.4, 5 Medication provides one treatment option, and the ghrelin agonist anamorelin was approved for this condition in the USA in 2017. This evidence concerns the gene GHRL and sarcopenia.